So the bad news is Intrepid trials are running 6 months behind.
They are bringing on new sites.
The Good news is
"On a positive note, the incidence of serious adverse events or SAEs continues to be very low as does mortality. We recently completed the reproductive toxicology studies that are necessary to initiate a pivotal trial and found no effects whatsoever on male or female fertility or reproductive fitness."
So does the Serious adverse events and low mortality, have a statistically significant result which makes NNZ-2566 approveable.
I imagine somebody at the AGM has got a definitive answer to that question.
I like a punt, so I would back it in that this will eventually be an approved drug.
At these prices the odds are too heavily stacked my way not to have a decent punt.
NEU Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)